News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Jaguar Health's Napo Pharmaceuticals submits orphan drug designation application to FDA for crofelemer in treating diarrhea in adult patients with breast cancer metastasized to the brain, targeting expedited regulatory pathways -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present at H.C. Wainwright 27th Annual Global Investment Conference. Lisa Conte to discuss pharmaceutical developments for gastrointestinal distress -
